Format

Send to

Choose Destination
J Pathol. 2019 Nov;249(3):319-331. doi: 10.1002/path.5319. Epub 2019 Aug 28.

Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma.

Author information

1
Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, Canada.
2
Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.
3
Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.
4
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
5
Department of Pathology, Faculty of Medicine, Menoufia University, Shebeen El-Kom, Egypt.
6
Texas Children's Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
7
Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, Los Angeles, CA, USA.
8
Department of Pathology, Keck School of Medicine of USC, Los Angeles, CA, USA.
9
Department of Human Genetics, McGill University and Research Institute, McGill University Health Centre, Montreal, Canada.
10
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
11
Division of Haematology-Oncology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada.

Abstract

Despite being the most common childhood bone tumor, the genomic characterization of osteosarcoma remains incomplete. In particular, very few osteosarcoma metastases have been sequenced to date, critical to better understand mechanisms of progression and evolution in this tumor. We performed an integrated whole genome and exome sequencing analysis of paired primary and metastatic pediatric osteosarcoma specimens to identify recurrent genomic alterations. Sequencing of 13 osteosarcoma patients including 13 primary, 10 metastatic, and 3 locally recurring tumors revealed a highly heterogeneous mutational landscape, including cases of hypermutation and microsatellite instability positivity, but with virtually no recurrent alterations except for mutations involving the tumor suppressor genes RB1 and TP53. At the germline level, we detected alterations in multiple cancer related genes in the majority of the cohort, including those potentially disrupting DNA damage response pathways. Metastases retained only a minimal number of short variants from their corresponding primary tumors, while copy number alterations showed higher conservation. One recurrently amplified gene, KDR, was highly expressed in advanced cases and associated with poor prognosis. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

KEYWORDS:

KDR; VEGF; childhood bone sarcomas; genome sequencing; metastasis; osteosarcoma

PMID:
31236944
DOI:
10.1002/path.5319

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center